GAIN THERAPEUTICS, INC Proceeds from Issuance or Sale of Equity
GAIN THERAPEUTICS, INC (GANX) reported Proceeds from Issuance or Sale of Equity of $11.50 million for the 4-month period ending 2024-09-30, per its 10-Q filed 2024-11-14.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOrSaleOfEquity · last filed 2025-03-27
- GAIN THERAPEUTICS, INC proceeds from issuance or sale of equity for the quarter ending 2023-12-31 was $10.10M.
| Period end | Proceeds from Issuance or Sale of Equity 1 month | Proceeds from Issuance or Sale of Equity 3 month | Proceeds from Issuance or Sale of Equity 4 month |
|---|---|---|---|
| 2024-09-30 | $11.50M 10-Q · filed 2024-11-14 | ||
| 2024-06-30 | $11.00M 10-Q · filed 2024-08-08 | ||
| 2023-12-31 | $10.10M 10-K · filed 2025-03-27 | ||
| 2023-11-30 | $10.10M 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B |